Genentech reports Phase II data of polatuzumab vedotin in DLBCL

In an abstract released ahead of the American Society of Hematology (ASH) meeting, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from 80 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) from the Phase II portion of a

Read the full 444 word article

User Sign In